About Adragos Pharma
Adragos Pharma is a Financial Services company based in Munchen (Germany) founded in 2020 by Andreas Raabe, and was acquired by FSN Capital in August 2021. It operates as a healthcare sector investments are managed by a private equity fund. Adragos Pharma has completed 2 acquisitions, including Baccinex and Lamda. Its chief executive is Andreas Raabe. Its website adragos-pharma.com draws about 38 thousand monthly visits. Its focus areas include Investment Industry, Private Equity Funds and Buyout Funds.
Company details
Adragos Pharma private equity fund investing in healthcare sectors through investment industry, private equity funds, and buyout funds. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Munchen, Germany
- Founders Andreas Raabe
- SectorsFinancial Services
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website adragos-pharma.com
- Social LinkedIn
- Acquired by FSN Capital (Aug 2021)
- Investors
- Investments & AcquisitionsBaccinex
& 1 more
- Acquired byFSN Capital
(Aug 2021)
Investors in Adragos Pharma
Adragos Pharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include FSN Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | fsncapital.com | - |
Investor details for Adragos Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adragos Pharma
37 people are tracked at Adragos Pharma (24 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
Andreas Raabe | Co-Founder & CEO | Leadership |
Jeff Morrod | Chairman of Board | Leadership |
Aggelos Karatzas | Managing Director | Leadership |
Masanori Kurugome | Director | Leadership |
Niels Erik Olsen | Vice Chairman of Board | Leadership |
Gael Le Saux | Director | Leadership |
Otto Prange | Board Member | Leadership |
Wayne Swanton | Board Member | Leadership |
Henny Zijlstra | Chief Commercial Officer | Leadership |
Stephanie Bova | Board Member | Leadership |
Katsoris Dimitris | Chief Accountant | Leadership |
Laura Mary | Director Of Business Development | Leadership |
Marco Gorgas | COO | Leadership |
Paola Perico Valcárcel | Head Of Marketing | Leadership |
Daniel Wigbers | CFO & CDO | Leadership |
Argyro Stappa | Head Of Research And Development | Leadership |
Bastian Baur | Global Head Of Digitalization & IT | Leadership |
Panagiotis Cholevas | Financial Director | Leadership |
Arne Jarsumbeck | Head Of Corporate Finance | Leadership |
Christina Koulouri | Head Of Project Management & Supply Chain | Leadership |
17 more people are available in the full profile.
Complete people profiles for Adragos Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adragos Pharma
Adragos Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Baccinex and Lamda.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
CDMO specializing in fill and finishing of sterile lyophilized or liquid dosage forms | baccinex.com | Courroux, Switzerland | 1999 | Nov 2024 | •••• | |
Laboratory focused on generic drugs development and research services | lamdalabs.eu | Koropi, Greece | 1996 | Mar 2023 | •••• |
Complete acquisition details for Adragos Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Adragos Pharma
The website of Adragos Pharma (adragos-pharma.com) receives about 37.7K visits a month and ranks #765,754 among all websites worldwide, #896 in Biotechnology and Pharmaceuticals.
- Monthly visits37.7K
▼ 8.8% vs previous month
- Unique visitors18.3K
per month
- Global rank#765,754
among all websites
- Category rank#896
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.9
- Average visit32 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Adragos Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nebiolab.com | 100% | 20.8K | #944,903 | View details | |
| patheon.com | 98% | 89.1K | #488,648 | View details | |
| bioagilytix.com | 97% | 41.6K | #919,146 | View details | |
| seikagaku.co.jp | 86% | 15.2K | #1,854,288 | View details | |
pharma-iq.com | pharma-iq.com | 79% | – | #1,426,511 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Adragos Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Private Equity Funds
10 companies that operate in the same segment as Adragos Pharma (Private Equity Funds), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Alternative asset investment management firm | 1997 | Los Angeles, California, United States | – | USD 6.2 B | 3,200 | |
Private equity firm and fund of funds focused on multiple sectors | 2020 | India | – | USD 238.01 M | 969 | |
Private equity and debt investments are managed for businesses. | 2004 | Los Angeles, California, United States | – | USD 3.15 B | 3,200 | |
Multiple sectors are invested in by this private equity firm. | 1976 | New York, New York, United States | – | USD 20.29 B | 4,830 | |
Acquisitions are targeted by Novacap, a private equity firm. | 1981 | Brossard, Quebec, Canada | – | – | 298 | |
Digital infrastructure and real estate investments are managed by DigitalBridge. | 2013 | Manchester, Greater Manchester, United Kingdom | – | USD 607.03 M | 324 | |
Limited information is provided about Onex's activities. | 1984 | Toronto, Ontario, Canada | – | USD 293.91 M | 373 | |
Data infrastructure companies are targeted for private equity investments. | 2001 | San Francisco, California, United States | – | – | 60 | |
Private equity investments are directed toward multiple sectors. | 1986 | Washington, District Of Columbia, United States | – | USD 4.79 B | 2,300 | |
A private equity firm focused on mid-market software leaders. | 1990 | Menlo Park, California, United States | – | USD 164.06 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adragos Pharma
Adragos Pharma was founded in 2020.
Adragos Pharma is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Andreas Raabe is the current CEO of Adragos Pharma. They have also founded this company.
Adragos Pharma private equity fund investing in healthcare sectors through investment industry, private equity funds, and buyout funds. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Adragos Pharma has 1 investor. Key investors include FSN Capital.
Yes. Adragos Pharma was acquired by FSN Capital in August 2021.